CoChat

The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception

Open access
Skelley, Jessica W., Swearengin, Katelyn, York, Adriane L., Glover, Lacey H. · 2024 · Journal of the American Pharmacists Association
Cited by 66

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

BACKGROUND Tirzepatide is a dual GLP-1 and gastric inhibitory polypeptide (GIP) receptor agonist whose mechanism of action leads to a greater effect of gastric emptying (GE) than typical Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). After the first dose of tirzepatide, gastric emptying is most substantially delayed. The drug then undergoes tachyphylaxis after subsequent doses. While data on GLP1-RAs has historically demonstrated a lack of impact on bioavailability of oral hormonal contraceptives, manufacturer recommendations for tirzepatide indicate an interaction exists. OBJECTIVES The objectives of this literature review were to review trial data on differences in impact of tirzepatide and GLP-1 RAs on oral hormonal contraceptives as well as provide an analysis of safety data between oral contraceptives and incretin agents. METHODS PubMed and Google Scholar were searched using the generic name for the GLP-1/GIP agent, the generic names for GLP-1 RAs and hormonal contraceptives, followed by the generic names plus the interacting medication. A total of six clinical trials were selected for inclusion in the literature review. RESULTS Of the six articles included in the review, one investigated the use of tirzepatide and showed a statistically significant reduction in AUC, Cmax, and Tmax when tirzepatide was concomitantly administered with an oral hormonal contraceptive. The remaining five studies involving GLP-1 RAs did not show a significant difference of impact of the agents on oral hormonal contraceptives. CONCLUSION In conclusion, it could be suggested that tirzepatide had a greater impact on absorption of oral hormonal contraceptives compared to other GLP-1 RAs. The rapid dose escalation and greater delay on GE enhanced the impact on oral medications such as contraceptives. This differed from other GLP-1 RAs and creates a unique need for enhanced provider and patient education regarding the management of this interaction as well as future studies to evaluate this interaction further.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.japh.2023.10.037

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 66

Metadata

Authors
Skelley, J. W., Swearengin, K., York, A. L., & Glover, L. H.
Venue
Journal of the American Pharmacists Association
Publisher
Elsevier BV
Published
2024-01
Volume
64
Issue
1
Pages
204-211.e4
ISSN
1544-3191 (ISSN-L)
OpenAlex
W4388461162
Cited by
66
References
11
FWCI
15.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. https://app.cochat.ai/papers/10.1016/j.japh.2023.10.037
The paper
Skelley, J. W., Swearengin, K., York, A. L., & Glover, L. H. (2024). The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association. https://doi.org/10.1016/j.japh.2023.10.037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.